Denosumab is primarily used in the treatment of osteoporosis, particularly in postmenopausal women who are at a high risk of fractures. It works by inhibiting bone resorption, thereby increasing bone mass and strength. This makes it an effective option for reducing the risk of vertebral, non-vertebral, and hip fractures. It is also utilized in the management of bone loss associated with hormone ablation therapy in patients with prostate or breast cancer. By preventing bone breakdown, it helps maintain skeletal integrity in these patients. Additionally, Denosumab is employed in the treatment of giant cell tumor of bone, a rare and aggressive type of tumor. It helps to control the growth of the tumor and reduce symptoms by targeting the cells responsible for bone destruction. In cases of hypercalcemia of malignancy that is resistant to bisphosphonate therapy, Denosumab can be used to lower elevated calcium levels in the blood, providing symptomatic relief. Overall, Denosumab plays a crucial role in various conditions where bone health is compromised, offering therapeutic benefits by targeting the underlying mechanisms of bone loss and destruction.